Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer

Gut

Volumn 59, Issue 1, 2010, Pages 69-78

  Kijanka, G ^a   Hector, S ^a   Kay, E W ^b   Murray, F ^b   Cummins, R ^a   Murphy, D ^a   MacCraith, B D ^c   Prehn, J H M ^a   Kenny, D ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CELL PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN G ANTIBODY; PROTEIN LASS5; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 3; TRIPARTITE MOTIF PROTEIN 28; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 346;

ADULT; AGED; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN MICROARRAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; SYMPTOM; TISSUE MICROARRAY;

AGED; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; COLONOSCOPY; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOGLOBULIN G; INTESTINAL MUCOSA; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 73449088038     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.178574     Document Type: Article

References (58)

1. Newcomb PA, Norfleet RG, Storer BE, et al. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992;84:1572-5.
2. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-71.
3. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
4. Koziol JA, Zhang JY, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003;9:5120-6.
5. Qiu J, Madoz-Gurpide J, Misek DE, et al. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 2004;3:261-7.
6. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353:1224-35.
7. Chen G, Wang X, Yu J, et al. Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res 2007;67:3461-7.
8. Fujita Y, Nakanishi T, Miyamoto Y, et al. Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett 2008;263:280-90.
9. Spiotto MT, Reth MA, Schreiber H. Genetic changes occurring in established tumors rapidly stimulate new antibody responses. Proc Natl Acad Sci USA 2003;100:5425-30.
10. Engelhorn ME, Guevara-Patino JA, Noffz G, et al. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med 2006;12:198-206.
11. Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 2001;108:1411-5.
12. Casiano CA, Mediavilla-Varela M, Tan EM. Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics 2006;5:1745-59.
13. Mintz PJ, Kim J, Do KA, et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2003;21:57-63.
14. Bussow K, Cahill D, Nietfeld W, et al. A method for global protein expression and antibody screening on high-density filters of an arrayed cDNA library. Nucleic Acids Res 1998;26:5007-8.
15. Bussow K, Nordhoff E, Lubbert C, et al. A human cDNA library for high-throughput protein expression screening. Genomics 2000;65:1-8.
16. Horn S, Lueking A, Murphy D, et al. Profiling humoral autoimmune repertoire of dilated cardiomyopathy (DCM) patients and development of a disease-associated protein chip. Proteomics 2006;6:605-13.
17. Johnson MR, Wang K, Smith JB, et al. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 2000;278:175-84.
18. Hector S, Bolanowska-Higdon W, Zdanowicz J, et al. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 2001;48:398-406.
19. Kay E, O'Grady A,Morgan JM, et al. Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing. J Clin Pathol 2004;57:1140-4.
20. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
21. Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity. BMJ 1994;308:1552.
22. Hammel P, Leroy-Viard K, Chaumette MT, et al. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Int J Cancer 1999;81:712-8.
23. Broll R, Duchrow M, Oevermann E, et al. p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue. Int J Colorectal Dis 2001;16:22-7.
24. Lechpammer M, Lukac J, Lechpammer S, et al. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis 2004;19:114-20.
25. Disis ML, Pupa SM, Gralow JR, et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997;15:3363-7.
26. Soussi T. p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000;60:1777-88.
27. Kuniyasu H, Chihara Y, Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 2003;10:445-8.
28. Volp K, Brezniceanu ML, Bosser S, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006;55:234-42.
29. Goodwin GH, Sanders C, Johns EW. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem 1973;38:14-9.
30. Kuramochi M, Fukuhara H, Nobukuni T, et al. TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 2001;27:427-30.
31. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11810-3.
32. Lubin R, Zalcman G, Bouchet L, et al. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995;1:701-2.
33. Trivers GE, Cawley HL, DeBenedetti VM, et al. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 1995;87:1400-7.
34. Trivers GE, De Benedetti VM, Cawley HL, et al. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 1996;2:1767-75.
35. Zhang JY, Casiano CA, Peng XX, et al. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003;12:136-43.
36. Kuniyasu H, Yano S, Sasaki T, et al. Colon cancer cell-derived high mobility group 1/ amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol 2005;166:751-60.
37. Stros M, Ozaki T, Bacikova A, et al. HMGB1 and HMGB2 cell-specifically downregulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem 2002;277:7157-64.
38. Yuan F, Gu L, Guo S, et al. Evidence for involvement of HMGB1 protein in human DNA mismatch repair. J Biol Chem 2004;279:20935-40.
39. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-5.
40. Huang JC, Zamble DB, Reardon JT, et al. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 1994;91:10394-8.
41. Nagatani G, Nomoto M, Takano H, et al. Transcriptional activation of the human HMG1 gene in cisplatin-resistant human cancer cells. Cancer Res 2001;61:1592-7.
42. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-60.
43. Ellerman JE, Brown CK, de Vera M, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007;13:2836-48.
44. Yu J, Mallon MA, Zhang W, et al. DNA repair pathway profiling and microsatellite instability in colorectal cancer. Clin Cancer Res 2006;12:5104-11.
45. Li X, Lee YK, Jeng JC, et al. Role for KAP1 serine 824 phosphorylation and sumoylation/desumoylation switch in regulating KAP1-mediated transcriptional repression. J Biol Chem 2007;282:36177-89.
46. Peng H, Zheng L, Lee WH, et al. A common DNA-binding site for SZF1 and the BRCA1-associated zinc finger protein, ZBRK1. Cancer Res 2002;62:3773-81.
47. White DE, Negorev D, Peng H, et al. KAP1, a novel substrate for PIKK family members, colocalizes with numerous damage response factors at DNA lesions. Cancer Res 2006;66:11594-9.
48. Goodarzi AA, Noon AT, Deckbar D, et al. ATM signaling facilitates repair of DNA double-strand breaks associated with heterochromatin. Mol Cell 2008;31:167-77.
49. Cammas F, Janoshazi A, Lerouge T, et al. Dynamic and selective interactions of the transcriptional corepressor TIF1 beta with the heterochromatin protein HP1 isotypes during cell differentiation. Differentiation 2007;75:627-37.
50. Tsuruma R, Ohbayashi N, Kamitani S, et al. Physical and functional interactions between STAT3 and KAP1. Oncogene 2008;27:3054-9.
51. Perez-Moreno MA, Locascio A, Rodrigo I, et al. A new role for E12/E47 in the repression of E-cadherin expression and epithelial- mesenchymal transitions. J Biol Chem 2001;276:27424-31.
52. Gregorieff A, Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev 2005;19:877-90.
53. Lahiri S, Futerman AH. LASS5 is a bona fide dihydroceramide synthase that selectively utilizes palmitoyl CoA as acyl donor. J Biol Chem 2005:280:33735-8.
54. Min J, Mesika A, Sivaguru M, et al. (Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1. Mol Cancer Res 2007;5:801-12.
55. Senkal CE, Ponnusamy S, Rossi MJ, et al. Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol Cancer Ther 2007;6:712-22.
56. Yang M, Wu S, Su X, et al. JAZ mediates G1 cell-cycle arrest and apoptosis by positively regulating p53 transcriptional activity. Blood 2006;108:4136-45.
57. Zinkernagel RM. What is missing in immunology to understand immunity? Nat Immunol 2000;1:181-5.
58. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.